Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma Inc. presents an attractive valuation supported by a net present value (NPV) analysis indicating significant upside potential from current share prices. The company's investigational drug assets, particularly IGC-AD1, have demonstrated encouraging results in preclinical studies for combating Alzheimer's disease, highlighting the effectiveness in addressing critical disease hallmarks. Additionally, ongoing advancements and the anticipation of positive data are expected to act as catalysts for stock performance moving forward.

Bears say

IGC Pharma Inc reported a net loss of $1.6 million, translating to an earnings per share (EPS) of $(0.02), which aligns with the company's prior estimates but raises concerns about ongoing financial viability. The company faces significant risks including liquidity issues, potential failure of its investigational drug candidates to prove safety and efficacy, and challenges related to regulatory approvals and market commercialization. Furthermore, external factors such as competition and changing investor sentiment towards biotech stocks add further uncertainty to the company's future performance and stock outlook.

IGC has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 2 analysts, IGC has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.